Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCAT 2024 | Musculoskeletal complications of SCD: distinguishing between vaso-occlusive events & osteomyelitis

Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Trust, London, UK, outlines a collaborative project with her radiology colleagues to create an atlas of radiological features commonly observed in patients with sickle cell disease (SCD), particularly pediatric patients. This effort aims to help clinicians and radiologists differentiate between vaso-occlusive events and osteomyelitis, two conditions that are difficult to distinguish but require different treatments. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria for participation in this meeting provided by Vertex Pharmaceuticals; Research funding: Pfizer, Global Blood Therapeutics, Forma therapeutics, Nova laboratories; Honoraria for EHA 2024 Congress: Vertex Pharmaceuticals, Sobi.